Parasite vaccine development: Large-scale recovery of immunogenic Taenia ovis fusion protein GST-45W(B/X) from Escherichia coli inclusion bodies

29Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Genetically modified Escherichia coli expressing the Taenia ovis fusion protein GST-45W(B/X) as inclusion bodies were grown in volumes ranging up to 1000 l. Bacteria were inactivated by heat or chemical treatment without affecting immunogenicity. The fusion protein was recovered in a highly immunogenic form from washed inclusion bodies and from urea-solubilised inclusion bodies. The fusion protein was found to be stable in solution after storage at 4°C for up to 2 years. Vaccines formulated with fusion protein from urea-soluble inclusion bodies gave consistently high protection (89-100%) against challenge infection. The methods described enabled the production of sufficient vaccine for large field trials. These trials generated the data required for product registration and manufacture of a vaccine to prevent T. ovis infection in sheep.

Cite

CITATION STYLE

APA

Dempster, R. P., Robinson, C. M., & Harrison, G. B. L. (1996). Parasite vaccine development: Large-scale recovery of immunogenic Taenia ovis fusion protein GST-45W(B/X) from Escherichia coli inclusion bodies. Parasitology Research, 82(4), 291–296. https://doi.org/10.1007/s004360050116

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free